Pre-clinical Evaluation Of Nano-membrane Dressings To Promote Wound Healing
Funder
National Health and Medical Research Council
Funding Amount
$188,600.00
Summary
This project will investigate whether a novel type of wound dressing can promote faster wound healing and reduce scarring. Time taken to heal is one of the best predictors of whether a wound will heal with significant scarring. The faster wounds heal the better. We have identified a new dressing with specific nano-scale pores that may promote faster healing. This dressing will be tested in the best model of human wound healing with the potential to progress to clinical trials if successful.
Studies Of Metabolites Of Synthetic Flavonols For The Treatment Of Cardiovascular Disease
Funder
National Health and Medical Research Council
Funding Amount
$207,440.00
Summary
Cardiovascular disease, including heart attack and stroke, is the leading killer of Australians. A promising new drug, NP202, can reduce the amount of tissue damaged from a heart attack; however, its mechanism of action remains obscure. NP202 is metabolized to a range of compounds, one of which is partly responsible for its beneficial effects. In this project we will identify other metabolites of NP202 and characterize their biological activity to gain insight into its mechanism of action.
Proof Of Concept Studies On A Novel Class Of Antibiotics
Funder
National Health and Medical Research Council
Funding Amount
$199,700.00
Summary
The rise of drug-resistant superbugs is a major healthcare concern in hospitals across the world. New antibiotics are needed to combat infections caused by bacteria that are resistant to current drugs. One collaborative team of researchers is addressing the issue. They have discovered a new compound effective against Staphylococcus aureus, the cause of Golden Staph. Using a combination of scientific disciplines the team are now developing this compound into a new antibiotic.
Production Of A Novel Humanised Anti Dendritic Cell Therapeutic Antibody For Graft Versus Host Disease
Funder
National Health and Medical Research Council
Funding Amount
$202,500.00
Summary
A transplant of bone marrow or other source of blood stem cells from a donor is often used to treat leukaemia patients whose disease has failed to respond to chemotherapy. The Mater Medical Research Institute has developed a world first dendritic cell depleting therapeutic antibody which may open a new strategy for the control of acute graft versus host disease, which is a very common and often fatal complication of bone marrow transplantation. The new antibody treatment is also likely to be use ....A transplant of bone marrow or other source of blood stem cells from a donor is often used to treat leukaemia patients whose disease has failed to respond to chemotherapy. The Mater Medical Research Institute has developed a world first dendritic cell depleting therapeutic antibody which may open a new strategy for the control of acute graft versus host disease, which is a very common and often fatal complication of bone marrow transplantation. The new antibody treatment is also likely to be useful for the prevention of rejection in solid organ transplantation. If successful, it will selectively control graft versus host disease, without compromising the essential anti-viral immunity and desired anti-leukemia activity of the graft.Read moreRead less